Method of treating ocular allergy

Details Method of treating ocular allergy Method of treating ocular allergy

2010-02-08

2011-10-11

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S546000, C514S558000

Reexamination Certificate

active

08034839

ABSTRACT:
The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.

REFERENCES:
patent: 5079261 (1992-01-01), Serhan et al.
patent: 6645978 (2003-11-01), Gamache et al.
patent: 2006/0058375 (2006-03-01), Klimko et al.
patent: 2006/0099248 (2006-05-01), Klimko et al.
patent: 2006/0154981 (2006-07-01), Klimko et al.
patent: 2008/0108695 (2008-05-01), Klimko et al.
patent: W003040080 (2003-05-01), None
patent: WO03039533 (2003-05-01), None
patent: WO2005112905 (2005-12-01), None
patent: WO2006052950 (2006-05-01), None
Leonard Bielory, et al., “Efficacy and Tolerability of Newer Antihistamines in the Treatment of Allergic Conjunctivitis,” Drugs, 2005, pp. 215-228, vol. 65(2).
C. Bonnans, et al., “Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation?” Allergy, 2004, pp. 1027-1041, vol. 59.
Nan Chiang, et al., “Activation of Lipoxin A4 Receptors by Aspirin-triggered Lipoxins and Select Peptides Evokes Ligand-specific Responses in Inflammation,” J. Exp. Med., Apr. 3, 2000, pp. 1197-1207, vol. 191, No. 7.
Stefano Fiore, et al., “Identification of a Human cDNA Encoding a Functional High Affinity Lipoxin A4 Receptor,” J. Exp. Med., Jul. 1994, pp. 253-260, vol. 180.
Stefano Fiorucci, et al., “A β-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction,” Proc. Nat. Acad. Sci., Nov. 2004, pp. 15736-15741, vol. 101, No. 44.
Felicity N. E. Gavins, et al., “Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related ani-inflammatory mechanisms,” Blood, May 15, 2003, pp. 41404147, vol. 101, No. 10.
Derek W. Gilroy, et al., “Inflammatory Resolution: New Opportunities for Drug Discovery,” Nature Reviews, May 2004, pp. 401-416, vol. 3.
Karsten Gronert, et al., “Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses,” American Journal of Pathology, Jan. 2001, vol. 158, No. 1.
Karsten Gronert, et al., “A role for the Mouse 12/15-Lipoxygenase Pathway in Promoting Epithelial Wound Healing and Host Defense,” Apr. 5, 2005, 15267-15278, vol. 280, No. 15.
William J. Guilford, et al., “Novel 3-Oxa Lipoxin A4 Analogues with Enhanced Chemical and Metabolic Stability Have Anti-inflammatory Activity in Vivo,” J. Med. Chem., 2004, pp. 2157-2165, vol. 47.
Levente Jozsef, et al., “Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kB and AP-1 activitation, and IL-8 gene expression in human leukocytes,” Proc. Nat. Acad. Sci., Oct. 1, 2002, pp. 13266-13271, vol. 99, No. 20.
Christopher L. Karp et al., “Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway,” Nature Immunology, Apr. 2004, pp. 388-392, vol. 5, No. 4.
Yingying Le, et al., “Pleiotropic roles of formyl peptide receptors,” Cytokine and Growth Factor Reviews, 2001, pp. 91-105, vol. 12.
Tak H. Lee, et al., “Inhibition of Leukotriene B4-Induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships,” Biochemical and Biophysical Research Communications, Nov. 14, 1991, pp. 1416-1421, vol. 180, No. 3.
Bruce D. Levy, et al., “Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4,” Nature Medicine, Sep. 2002, pp. 1018-1023, vol. 8, No. 9.
King-Teh Lin, et al., “Modulation of LTB4 Receptor in T-Lymphocytes by Lipoxin A4 (LXA4) and its Role in Delayed-Type Hypersensitivity,” Advances in Experimental Medicine and Biolog 1999 pp. 151-163, vol. 447.
Christianne Bandeira-Melo, et al., “Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking,” J. of Immunology , 2000, pp. 2267-2271, vol. 164.
Santa Jeremy Ono, et al., “Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment,” J. Allergy Clin Immunol., 2005, pp. 118-122, vol. 115.
Luca Parente, et al., “Annexin 1: more than an anti-phospholipase protein,” Inflammation Res., pp. 125-132, vol. 53.
Mauro Perretti, et al., “Endogenous lipid-and peptide-derived anti-inflammatory pathways operated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor,” Nature Medicine, Nov. 2002, pp. 1296-1302, vol. 8, No. 11.
Nicos A. Petasis, et al., “Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, 2005, pp. 301-321, vol. 73.
Arndt J. Schottelius, et al., “An Aspirin-Triggered Lipoxin A4 Stable Analog Displays a Unique Topical Anti-Inflammatory Profile,” J. of Immunology 2002, pp. 7063-7070, vol. 169.
Isabelle Vachier, et al., “Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound,” J. Allergy Clin. Immunol. 2005, pp. 65-60, vol. 115.
Mitchell H. Friedlaender, “Conjunctivitis,” The Merck Manual of Patient Symptoms (retrieved from Internet: URL:http://www.merck.com/mmpe/sec09/ch101/ch101c.html), Jun. 2008.
PCT/US2010/02351, International Search Report, Date of Mailing: Jun. 2, 2010.

Affiliated with

Also associated with

Rating

Method of treating ocular allergy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating ocular allergy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating ocular allergy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4295652